Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · Real-Time Price · USD
3.910
-0.150 (-3.69%)
At close: Aug 1, 2025, 4:00 PM
3.950
+0.040 (1.02%)
After-hours: Aug 1, 2025, 7:56 PM EDT

Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.

It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.

The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.

The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.

Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.
Sana Biotechnology logo
CountryUnited States
Founded2018
IPO DateFeb 4, 2021
IndustryBiotechnology
SectorHealthcare
Employees194
CEOSteven Harr

Contact Details

Address:
188 East Blaine Street, Suite 400
Seattle, Washington 98102
United States
Phone206 701 7914
Websitesana.com

Stock Details

Ticker SymbolSANA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$25.00
CIK Code0001770121
CUSIP Number799566104
ISIN NumberUS7995661045
SIC Code2836

Key Executives

NamePosition
Dr. Steven D. Harr M.D.President, Chief Executive Officer and Director
Bernard J. Cassidy J.D.Executive Vice President, General Counsel and Corporate Secretary
Susan WyrickActing Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance and Accounting
Snehal PatelSenior Vice President and Chief Technical Officer
Dr. Dhavalkumar D. Patel M.D., Ph.D.Executive Vice President and Chief Scientific Officer
Dr. Sonja Schrepfer M.D., Ph.D.Senior Vice President and Head of Hypoimmune Platform
Dr. Gary Meininger M.D.Chief Medical Officer
Dr. Yuko Soneoka J.D., Ph.D.Head of Intellectual Property
John Gerecitano M.D., Ph.D.Head of Oncology Research and Development

Latest SEC Filings

DateTypeTitle
Jun 23, 20258-KCurrent Report
Jun 6, 20258-KCurrent Report
May 8, 2025424B5Filing
May 8, 2025S-8Securities to be offered to employees in employee benefit plans
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 25, 2025SCHEDULE 13G/AFiling
Apr 25, 2025ARSFiling
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements